Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines

The anti-tumor effect of cyclo-oxygenase (COX) inhibitors has been documented in several studies. COX2 inhibitors have attracted more attention because of the fewer side-effects and the more prominent anti-tumor effects. However, experience with these drugs in hematological malignancies is limited....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 2005-05, Vol.46 (5), p.753-756
Hauptverfasser:	Vural, Filiz, Özcan, Mehmet Ali, Özsan, Güner Hayri, Ate, Halil, Demirkan, Fatih, Pi kin, Özden, Ündar, Bülent
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Butanones - pharmacology Cell Line, Tumor chronic myeloid leukemia Cyclo-oxygenase Cyclooxygenase Inhibitors - pharmacology Doxorubicin - administration & dosage Drug Screening Assays, Antitumor Flow Cytometry Humans K562 Cells Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Nabumetone Proto-Oncogene Proteins c-bcl-2 - biosynthesis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!